ID   KCC2G_HUMAN             Reviewed;         558 AA.
AC   Q13555; A0A0A0MS52; A0A0A0MT11; O00561; O15378; Q13279; Q13282; Q13556;
AC   Q5SQZ3; Q5SQZ4; Q5SWX4; Q7KYX5; Q8N4I3; Q8NIA4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 4.
DT   12-OCT-2022, entry version 214.
DE   RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit gamma;
DE            Short=CaM kinase II subunit gamma;
DE            Short=CaMK-II subunit gamma;
DE            EC=2.7.11.17;
GN   Name=CAMK2G; Synonyms=CAMK, CAMK-II, CAMKG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-36.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND VARIANT PRO-36.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-315.
RX   PubMed=9240463; DOI=10.1006/bbrc.1997.6871;
RA   Breen M.A., Ashcroft S.J.;
RT   "Human islets of Langerhans express multiple isoforms of
RT   calcium/calmodulin-dependent protein kinase II.";
RL   Biochem. Biophys. Res. Commun. 236:473-478(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 23-558, AND ALTERNATIVE SPLICING
RP   (ISOFORM 6).
RX   PubMed=12032636; DOI=10.1007/s00125-002-0779-8;
RA   Gloyn A.L., Desai M., Clark A., Levy J.C., Holman R.R., Frayling T.M.,
RA   Hattersley A.T., Ashcroft S.J.;
RT   "Human calcium/calmodulin-dependent protein kinase II gamma: cloning,
RT   genomic structure and detection of variants in subjects with type II
RT   diabetes.";
RL   Diabetologia 45:580-583(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 66-436 (ISOFORM 10).
RX   PubMed=8449910; DOI=10.1016/s0021-9258(18)53345-7;
RA   Nghiem P., Saati S.M., Martens C.L., Gardner P., Schulman H.;
RT   "Cloning and analysis of two new isoforms of multifunctional
RT   Ca2+/calmodulin-dependent protein kinase. Expression in multiple human
RT   tissues.";
RL   J. Biol. Chem. 268:5471-5479(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 302-497 (ISOFORMS 2 AND 4).
RX   PubMed=9060999; DOI=10.1016/s0167-4889(96)00141-3;
RA   Tombes R.M., Krystal G.W.;
RT   "Identification of novel human tumor cell-specific CaMK-II variants.";
RL   Biochim. Biophys. Acta 1355:281-292(1997).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 326-432 (ISOFORMS 7; 8 AND 9).
RX   PubMed=7557101; DOI=10.1016/0016-5085(95)90594-4;
RA   Kwiatkowski A.P., McGill J.M.;
RT   "Human biliary epithelial cell line Mz-ChA-1 expresses new isoforms of
RT   calmodulin-dependent protein kinase II.";
RL   Gastroenterology 109:1316-1323(1995).
RN   [9]
RP   ACTIVITY REGULATION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=14722083; DOI=10.1074/jbc.m313597200;
RA   Gaertner T.R., Kolodziej S.J., Wang D., Kobayashi R., Koomen J.M.,
RA   Stoops J.K., Waxham M.N.;
RT   "Comparative analyses of the three-dimensional structures and enzymatic
RT   properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin-
RT   dependent protein kinase II.";
RL   J. Biol. Chem. 279:12484-12494(2004).
RN   [10]
RP   FUNCTION IN SKELETAL MUSCLE, PHOSPHORYLATION AT THR-287, FUNCTION IN
RP   PHOSPHORYLATION OF PLN, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=16690701; DOI=10.1113/jphysiol.2006.111757;
RA   Rose A.J., Kiens B., Richter E.A.;
RT   "Ca2+-calmodulin-dependent protein kinase expression and signalling in
RT   skeletal muscle during exercise.";
RL   J. Physiol. (Lond.) 574:889-903(2006).
RN   [11]
RP   REVIEW ON FUNCTION IN SKELETAL MUSCLE.
RX   PubMed=15294044; DOI=10.1079/pns2004335;
RA   Chin E.R.;
RT   "The role of calcium and calcium/calmodulin-dependent kinases in skeletal
RT   muscle plasticity and mitochondrial biogenesis.";
RL   Proc. Nutr. Soc. 63:279-286(2004).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-311; SER-349; SER-352 AND
RP   SER-419, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-325 (ISOFORMS 10;
RP   11; 2; 3; 5; 6; 7; 8 AND 9), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT
RP   SER-346 (ISOFORM 11), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-338
RP   (ISOFORM 9), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-287; SER-311; SER-352 AND
RP   SER-419, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-325 (ISOFORMS 10; 2;
RP   3; 7; 8 AND 9), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-346 (ISOFORM
RP   11), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-311, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-287 AND SER-419, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-419, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 5-315 AND 426-556 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=20668654; DOI=10.1371/journal.pbio.1000426;
RA   Rellos P., Pike A.C., Niesen F.H., Salah E., Lee W.H., von Delft F.,
RA   Knapp S.;
RT   "Structure of the CaMKIIdelta/calmodulin complex reveals the molecular
RT   mechanism of CaMKII kinase activation.";
RL   PLoS Biol. 8:E1000426-E1000426(2010).
RN   [20]
RP   VARIANT MRD59 PRO-292, AND INVOLVEMENT IN MRD59.
RX   PubMed=23033978; DOI=10.1056/nejmoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C.,
RA   del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G.,
RA   Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
RN   [21]
RP   VARIANT MRD59 PRO-292, INVOLVEMENT IN MRD59, FUNCTION, AND CHARACTERIZATION
RP   OF VARIANT MRD59 PRO-292.
RX   PubMed=30184290; DOI=10.1002/humu.23647;
RA   Proietti Onori M., Koopal B., Everman D.B., Worthington J.D., Jones J.R.,
RA   Ploeg M.A., Mientjes E., van Bon B.W., Kleefstra T., Schulman H.,
RA   Kushner S.A., Kuery S., Elgersma Y., van Woerden G.M.;
RT   "The intellectual disability-associated CAMK2G p.Arg292Pro mutation acts as
RT   a pathogenic gain-of-function.";
RL   Hum. Mutat. 39:2008-2024(2018).
CC   -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that functions
CC       autonomously after Ca(2+)/calmodulin-binding and autophosphorylation,
CC       and is involved in sarcoplasmic reticulum Ca(2+) transport in skeletal
CC       muscle and may function in dendritic spine and synapse formation and
CC       neuronal plasticity (PubMed:16690701). In slow-twitch muscles, is
CC       involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport
CC       and in fast-twitch muscle participates in the control of Ca(2+) release
CC       from the SR through phosphorylation of the ryanodine receptor-coupling
CC       factor triadin (PubMed:16690701). In the central nervous system, it is
CC       involved in the regulation of neurite formation and arborization
CC       (PubMed:30184290). It may participate in the promotion of dendritic
CC       spine and synapse formation and maintenance of synaptic plasticity
CC       which enables long-term potentiation (LTP) and hippocampus-dependent
CC       learning. In response to interferon-gamma (IFN-gamma) stimulation,
CC       catalyzes phosphorylation of STAT1, stimulating the JAK-STAT signaling
CC       pathway (By similarity). {ECO:0000250|UniProtKB:Q923T9,
CC       ECO:0000269|PubMed:16690701, ECO:0000269|PubMed:30184290}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.17;
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of
CC       calmodulin results in conformational change that relieves intrasteric
CC       autoinhibition and allows autophosphorylation of Thr-287 which turns
CC       the kinase in a constitutively active form and confers to the kinase a
CC       Ca(2+)-independent activity. {ECO:0000269|PubMed:14722083}.
CC   -!- SUBUNIT: CAMK2 is composed of 4 different chains: alpha (CAMK2A), beta
CC       (CAMK2B), gamma (CAMK2G), and delta (CAMK2D). The different isoforms
CC       assemble into homo- or heteromultimeric holoenzymes composed of 12
CC       subunits with two hexameric rings stacked one on top of the other.
CC       {ECO:0000269|PubMed:14722083, ECO:0000269|PubMed:20668654}.
CC   -!- INTERACTION:
CC       Q13555; Q13557: CAMK2D; NbExp=3; IntAct=EBI-1383465, EBI-351018;
CC       Q13555; Q13555: CAMK2G; NbExp=2; IntAct=EBI-1383465, EBI-1383465;
CC       Q13555; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1383465, EBI-352572;
CC       Q13555-5; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-12020154, EBI-1383687;
CC       Q13555-5; Q13554-3: CAMK2B; NbExp=3; IntAct=EBI-12020154, EBI-11523526;
CC       Q13555-5; Q13557-8: CAMK2D; NbExp=3; IntAct=EBI-12020154, EBI-11534483;
CC       Q13555-5; Q16543: CDC37; NbExp=3; IntAct=EBI-12020154, EBI-295634;
CC       Q13555-5; Q6P1R4: DUS1L; NbExp=3; IntAct=EBI-12020154, EBI-6660325;
CC       Q13555-5; P62508-3: ESRRG; NbExp=3; IntAct=EBI-12020154, EBI-12001340;
CC       Q13555-5; Q63ZY3: KANK2; NbExp=3; IntAct=EBI-12020154, EBI-2556193;
CC       Q13555-5; Q7Z4W3: KRTAP19-3; NbExp=3; IntAct=EBI-12020154, EBI-12020132;
CC       Q13555-5; Q3LI64: KRTAP6-1; NbExp=3; IntAct=EBI-12020154, EBI-12111050;
CC       Q13555-5; Q9Y3B7: MRPL11; NbExp=3; IntAct=EBI-12020154, EBI-5453723;
CC       Q13555-5; P61970: NUTF2; NbExp=3; IntAct=EBI-12020154, EBI-591778;
CC       Q13555-5; Q9UBU9: NXF1; NbExp=3; IntAct=EBI-12020154, EBI-398874;
CC       Q13555-5; P20618: PSMB1; NbExp=3; IntAct=EBI-12020154, EBI-372273;
CC       Q13555-5; Q96SI9: STRBP; NbExp=3; IntAct=EBI-12020154, EBI-740355;
CC       Q13555-5; O14787-2: TNPO2; NbExp=3; IntAct=EBI-12020154, EBI-12076664;
CC       Q13555-5; Q9Y5L0: TNPO3; NbExp=3; IntAct=EBI-12020154, EBI-1042571;
CC       Q13555-5; Q8N0Z6: TTC5; NbExp=3; IntAct=EBI-12020154, EBI-9526213;
CC       Q13555-5; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-12020154, EBI-10180829;
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane {ECO:0000305};
CC       Peripheral membrane protein {ECO:0000305}; Cytoplasmic side
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC       Name=1;
CC         IsoId=Q13555-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13555-2; Sequence=VSP_013349;
CC       Name=3;
CC         IsoId=Q13555-3; Sequence=VSP_013350;
CC       Name=4;
CC         IsoId=Q13555-4; Sequence=VSP_004778;
CC       Name=5;
CC         IsoId=Q13555-5; Sequence=VSP_032699, VSP_032700, VSP_004778;
CC       Name=6;
CC         IsoId=Q13555-6; Sequence=VSP_032699, VSP_035456;
CC       Name=7; Synonyms=gamma F;
CC         IsoId=Q13555-7; Sequence=VSP_013350, VSP_035456;
CC       Name=8; Synonyms=gamma E;
CC         IsoId=Q13555-8; Sequence=VSP_013349, VSP_035456;
CC       Name=9; Synonyms=gamma D;
CC         IsoId=Q13555-9; Sequence=VSP_013349, VSP_036027, VSP_035456;
CC       Name=10;
CC         IsoId=Q13555-10; Sequence=VSP_013350, VSP_004778;
CC       Name=11;
CC         IsoId=Q13555-11; Sequence=VSP_059393, VSP_013349, VSP_059394;
CC   -!- TISSUE SPECIFICITY: Expressed in skeletal muscle.
CC       {ECO:0000269|PubMed:16690701}.
CC   -!- INDUCTION: Activity is induced in skeletal muscle during exercise.
CC       {ECO:0000269|PubMed:16690701}.
CC   -!- DOMAIN: The CAMK2 protein kinases contain a unique C-terminal subunit
CC       association domain responsible for oligomerization.
CC   -!- PTM: Autophosphorylation of Thr-287 following activation by
CC       Ca(2+)/calmodulin. Phosphorylation of Thr-287 locks the kinase into an
CC       activated state. {ECO:0000269|PubMed:14722083,
CC       ECO:0000269|PubMed:16690701}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 59
CC       (MRD59) [MIM:618522]: An autosomal dominant form of intellectual
CC       disability, a disorder characterized by significantly below average
CC       general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:30184290}. Note=The
CC       disease may be caused by variants affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. CaMK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB61379.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC022400; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL596247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713896; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF455257; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471083; EAW54527.1; -; Genomic_DNA.
DR   EMBL; CH471083; EAW54532.1; -; Genomic_DNA.
DR   EMBL; CH471083; EAW54536.1; -; Genomic_DNA.
DR   EMBL; BC034044; AAH34044.1; -; mRNA.
DR   EMBL; U66064; AAB80848.1; -; mRNA.
DR   EMBL; AH011636; AAM33514.1; -; Genomic_DNA.
DR   EMBL; L07043; AAB61379.1; ALT_INIT; mRNA.
DR   EMBL; U50359; AAB16864.1; -; mRNA.
DR   EMBL; U50360; AAB16865.1; -; mRNA.
DR   EMBL; U32472; AAA75201.1; -; mRNA.
DR   EMBL; U32473; AAA75202.1; -; mRNA.
DR   EMBL; U32509; AAA75203.1; -; mRNA.
DR   CCDS; CCDS73153.1; -. [Q13555-11]
DR   CCDS; CCDS7336.1; -. [Q13555-10]
DR   CCDS; CCDS7337.1; -. [Q13555-5]
DR   CCDS; CCDS7338.1; -. [Q13555-8]
DR   PIR; G01975; G01975.
DR   PIR; G01978; G01978.
DR   RefSeq; NP_001191421.1; NM_001204492.1. [Q13555-11]
DR   RefSeq; NP_001213.2; NM_001222.3. [Q13555-10]
DR   RefSeq; NP_001307827.1; NM_001320898.1.
DR   RefSeq; NP_751909.1; NM_172169.2. [Q13555-5]
DR   RefSeq; NP_751913.1; NM_172173.2.
DR   RefSeq; XP_005270260.1; XM_005270203.1.
DR   PDB; 2UX0; X-ray; 2.46 A; A/B/C/D/E/F=426-558.
DR   PDB; 2V7O; X-ray; 2.25 A; A=5-315.
DR   PDBsum; 2UX0; -.
DR   PDBsum; 2V7O; -.
DR   AlphaFoldDB; Q13555; -.
DR   SMR; Q13555; -.
DR   BioGRID; 107268; 182.
DR   DIP; DIP-51315N; -.
DR   IntAct; Q13555; 98.
DR   MINT; Q13555; -.
DR   STRING; 9606.ENSP00000319060; -.
DR   BindingDB; Q13555; -.
DR   ChEMBL; CHEMBL3829; -.
DR   DrugBank; DB08699; 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13555; -.
DR   GuidetoPHARMACOLOGY; 1557; -.
DR   TCDB; 8.A.104.1.12; the 5'-amp-activated protein kinase (ampk) family.
DR   iPTMnet; Q13555; -.
DR   PhosphoSitePlus; Q13555; -.
DR   BioMuta; CAMK2G; -.
DR   DMDM; 62512173; -.
DR   EPD; Q13555; -.
DR   jPOST; Q13555; -.
DR   MassIVE; Q13555; -.
DR   MaxQB; Q13555; -.
DR   PaxDb; Q13555; -.
DR   PeptideAtlas; Q13555; -.
DR   PRIDE; Q13555; -.
DR   ProteomicsDB; 59538; -. [Q13555-1]
DR   ProteomicsDB; 59539; -. [Q13555-10]
DR   ProteomicsDB; 59540; -. [Q13555-2]
DR   ProteomicsDB; 59541; -. [Q13555-3]
DR   ProteomicsDB; 59542; -. [Q13555-4]
DR   ProteomicsDB; 59543; -. [Q13555-5]
DR   ProteomicsDB; 59544; -. [Q13555-6]
DR   ProteomicsDB; 59545; -. [Q13555-7]
DR   ProteomicsDB; 59546; -. [Q13555-8]
DR   ProteomicsDB; 59547; -. [Q13555-9]
DR   Antibodypedia; 29531; 421 antibodies from 34 providers.
DR   DNASU; 818; -.
DR   Ensembl; ENST00000305762.11; ENSP00000307082.7; ENSG00000148660.21. [Q13555-4]
DR   Ensembl; ENST00000322635.7; ENSP00000315599.3; ENSG00000148660.21. [Q13555-5]
DR   Ensembl; ENST00000351293.7; ENSP00000277853.5; ENSG00000148660.21. [Q13555-10]
DR   Ensembl; ENST00000680035.1; ENSP00000505103.1; ENSG00000148660.21. [Q13555-11]
DR   GeneID; 818; -.
DR   KEGG; hsa:818; -.
DR   UCSC; uc001jvm.2; human. [Q13555-1]
DR   UCSC; uc001jvs.2; human.
DR   UCSC; uc057uec.1; human.
DR   CTD; 818; -.
DR   DisGeNET; 818; -.
DR   GeneCards; CAMK2G; -.
DR   HGNC; HGNC:1463; CAMK2G.
DR   HPA; ENSG00000148660; Tissue enhanced (skeletal).
DR   MalaCards; CAMK2G; -.
DR   MIM; 602123; gene.
DR   MIM; 618522; phenotype.
DR   neXtProt; NX_Q13555; -.
DR   OpenTargets; ENSG00000148660; -.
DR   PharmGKB; PA93; -.
DR   VEuPathDB; HostDB:ENSG00000148660; -.
DR   eggNOG; KOG0033; Eukaryota.
DR   GeneTree; ENSGT00940000156481; -.
DR   HOGENOM; CLU_000288_71_0_1; -.
DR   InParanoid; Q13555; -.
DR   OMA; MANPNRE; -.
DR   OrthoDB; 330091at2759; -.
DR   PhylomeDB; Q13555; -.
DR   TreeFam; TF315229; -.
DR   BRENDA; 2.7.11.17; 2681.
DR   PathwayCommons; Q13555; -.
DR   Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB.
DR   Reactome; R-HSA-3371571; HSF1-dependent transactivation.
DR   Reactome; R-HSA-399719; Trafficking of AMPA receptors.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde.
DR   Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors.
DR   Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission.
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; Q13555; -.
DR   SIGNOR; Q13555; -.
DR   BioGRID-ORCS; 818; 14 hits in 1116 CRISPR screens.
DR   ChiTaRS; CAMK2G; human.
DR   EvolutionaryTrace; Q13555; -.
DR   GeneWiki; CAMK2G; -.
DR   GenomeRNAi; 818; -.
DR   Pharos; Q13555; Tchem.
DR   PRO; PR:Q13555; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q13555; protein.
DR   Bgee; ENSG00000148660; Expressed in frontal pole and 191 other tissues.
DR   ExpressionAtlas; Q13555; baseline and differential.
DR   Genevisible; Q13555; HS.
DR   GO; GO:0005954; C:calcium- and calmodulin-dependent protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004723; F:calcium-dependent protein serine/threonine phosphatase activity; NAS:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0030073; P:insulin secretion; NAS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0051924; P:regulation of calcium ion transport; TAS:UniProtKB.
DR   GO; GO:0010975; P:regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0014733; P:regulation of skeletal muscle adaptation; TAS:UniProtKB.
DR   InterPro; IPR013543; Ca/CaM-dep_prot_kinase-assoc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR032710; NTF2-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF08332; CaMKII_AD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54427; SSF54427; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calmodulin-binding;
KW   Developmental protein; Differentiation; Intellectual disability; Kinase;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Sarcoplasmic reticulum;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..558
FT                   /note="Calcium/calmodulin-dependent protein kinase type II
FT                   subunit gamma"
FT                   /id="PRO_0000086101"
FT   DOMAIN          14..272
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          283..292
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000305|PubMed:20668654"
FT   REGION          294..316
FT                   /note="Calmodulin-binding"
FT                   /evidence="ECO:0000305|PubMed:20668654"
FT   REGION          324..353
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          376..423
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        336..353
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        386..404
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        408..423
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        136
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         20..28
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         43
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         287
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16690701,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         306
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         307
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11730"
FT   MOD_RES         349
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         352
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         484
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11730"
FT   VAR_SEQ         315
FT                   /note="S -> SVGRQSSAPASPAASAAGLAGQ (in isoform 5 and
FT                   isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_032699"
FT   VAR_SEQ         316
FT                   /note="A -> VGRQSSAPASPAASAAGLAGQA (in isoform 11)"
FT                   /id="VSP_059393"
FT   VAR_SEQ         331..364
FT                   /note="Missing (in isoform 3, isoform 7 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:7557101,
FT                   ECO:0000303|PubMed:8449910"
FT                   /id="VSP_013350"
FT   VAR_SEQ         331..341
FT                   /note="Missing (in isoform 2, isoform 8, isoform 9 and
FT                   isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:7557101,
FT                   ECO:0000303|PubMed:9060999"
FT                   /id="VSP_013349"
FT   VAR_SEQ         341..363
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_032700"
FT   VAR_SEQ         351..364
FT                   /note="Missing (in isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:7557101"
FT                   /id="VSP_036027"
FT   VAR_SEQ         396..426
FT                   /note="GRVPEGRSSRDRTAPSAGMQPQPSLCSSAMR -> VR (in isoform
FT                   11)"
FT                   /id="VSP_059394"
FT   VAR_SEQ         396..425
FT                   /note="GRVPEGRSSRDRTAPSAGMQPQPSLCSSAM -> V (in isoform 4,
FT                   isoform 5 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8449910, ECO:0000303|PubMed:9060999"
FT                   /id="VSP_004778"
FT   VAR_SEQ         397..398
FT                   /note="RV -> APLRTGNGSSV (in isoform 6, isoform 7, isoform
FT                   8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:7557101"
FT                   /id="VSP_035456"
FT   VARIANT         36
FT                   /note="S -> P (in dbSNP:rs17853266)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.2"
FT                   /id="VAR_042430"
FT   VARIANT         292
FT                   /note="R -> P (in MRD59; gain-of-function variant affecting
FT                   regulation of neurite formation and arborization; results
FT                   in constitutive autophosphorylation; dbSNP:rs397514627)"
FT                   /evidence="ECO:0000269|PubMed:23033978,
FT                   ECO:0000269|PubMed:30184290"
FT                   /id="VAR_069390"
FT   CONFLICT        230
FT                   /note="A -> T (in Ref. 6; AAB61379)"
FT                   /evidence="ECO:0000305"
FT   HELIX           9..13
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          14..22
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          26..33
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   TURN            34..37
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          38..46
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           52..67
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          76..81
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          83..91
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           98..103
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           110..129
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          142..145
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   STRAND          153..155
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           178..180
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           183..187
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           194..209
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           219..227
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           237..240
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           243..252
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   TURN            257..259
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           263..266
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           270..273
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           275..278
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           285..301
FT                   /evidence="ECO:0007829|PDB:2V7O"
FT   HELIX           425..443
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   HELIX           446..452
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   STRAND          453..460
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   HELIX           462..464
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   STRAND          468..470
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   HELIX           471..481
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   TURN            482..485
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   STRAND          490..501
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   STRAND          506..518
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   STRAND          524..538
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   STRAND          541..550
FT                   /evidence="ECO:0007829|PDB:2UX0"
FT   MOD_RES         Q13555-2:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q13555-3:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q13555-5:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         Q13555-6:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         Q13555-7:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q13555-8:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q13555-9:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q13555-9:338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         Q13555-10:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         Q13555-11:325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         Q13555-11:346
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
SQ   SEQUENCE   558 AA;  62607 MW;  7D61AB799B8F8CEB CRC64;
     MATTATCTRF TDDYQLFEEL GKGAFSVVRR CVKKTSTQEY AAKIINTKKL SARDHQKLER
     EARICRLLKH PNIVRLHDSI SEEGFHYLVF DLVTGGELFE DIVAREYYSE ADASHCIHQI
     LESVNHIHQH DIVHRDLKPE NLLLASKCKG AAVKLADFGL AIEVQGEQQA WFGFAGTPGY
     LSPEVLRKDP YGKPVDIWAC GVILYILLVG YPPFWDEDQH KLYQQIKAGA YDFPSPEWDT
     VTPEAKNLIN QMLTINPAKR ITADQALKHP WVCQRSTVAS MMHRQETVEC LRKFNARRKL
     KGAILTTMLV SRNFSAAKSL LNKKSDGGVK KRKSSSSVHL MPQSNNKNSL VSPAQEPAPL
     QTAMEPQTTV VHNATDGIKG STESCNTTTE DEDLKGRVPE GRSSRDRTAP SAGMQPQPSL
     CSSAMRKQEI IKITEQLIEA INNGDFEAYT KICDPGLTSF EPEALGNLVE GMDFHKFYFE
     NLLSKNSKPI HTTILNPHVH VIGEDAACIA YIRLTQYIDG QGRPRTSQSE ETRVWHRRDG
     KWLNVHYHCS GAPAAPLQ
//
